Senari Pharma is a seed-stage pharma company targeting a $2bn market through the development of an inhaled therapeutic for obstructive lung disease using known molecules in a novel way. The company is raising $20M to fund progress through to Phase 1 and 2 clinical trials with a view to a potential exit prior to Phase 3. Senari's product will be differentiated through its unique formulation in order to resonate with prescribers and opinion leaders. The company is reducing the risk of formulation development and time to market through leveraging well-established inactive ingredients and device components and aims to initiate Phase 1 in Q4 2021. Senari is led by Dr Sanjeeva Dissanayake, CEO and Founder, who has 20 years' experience in the pharmaceutical industry that includes five major multinational regulatory approvals. The management team is completed by two senior pharmaceutical executives: Dr Anne Brindley, a recognised industry expert in inhaled product development with a central role in the approval of two major inhaled product brands; and Peter McGowan a high calibre and commercially astute CFO with 30 years of pharma experience in both start up and established organisations.